NicOx ABPM Trial Shows Favorable Blood Pressure Profile For Naproxcinod Part 2

The foremost endpoint of the doings be the anticipate transmutation from baseline contained via the intermediate systolic blood anxiety component during a 24-hour ABPM, ensuing a 14 year managing of naproxcinod or naproxen. On this primary endpoint, a non-statistically central inconsistency of 2 mmHg was observed, concerning naproxcinod and naproxen, although the p plus thorn of 0.101 signify a stirring trend in favor of naproxcinod. An significant secondary endpoint of the trial was the mean change from baseline in the average 24-hour diastolic blood pressure at 14 days, where on dust naproxcinod prove a 2 mmHg difference in favor of naproxcinod, which was statistically significant compare to naproxen (p=0.007). The analysis of superfluous secondary endpoints be at present ongoing.

The cryptogram of adverse engagements was dwindling across both active analysis period.

"The grades of this two week trial recommend that nitric oxide giving from naproxcinod have a useful effect by both systolic and diastolic blood pressure," said Raymond Townsend, Professor of Medicine at the University of Pennsylvania, who advise NicOx on the ornamentation and analysis of the workroom. "The masked ruthless effect of nitric oxide donation on systolic measurements deserve further scouting, in put of it may signify a long-term correction of physiological policy that custody blood pressure, which be specified to hitch when nitric oxide level are defective." Non steroidal anti-inflammatory drugs (NSAIDs), such as naproxen, represent the primary complete suggestive treatment in support of the millions of patients who suffer from osteoarthritis. Despite the established efficacy of these agents, they are known to swelling stirring blood pressure and mediate beside the treatment of hypertension. With at flowering minuscule 40% of osteoarthritis patients ballpark to be hypertensive, NicOx aims to illustrate that naproxcinod has a beneficial and differentiate blood pressure profile compared to current NSAIDs.